Expert: House Stem Cell Questions Are ‘Spot On,’ FDA Must Do More

By David Roza / July 26, 2019 at 1:08 PM
A cell biologist praised House Energy & Commerce Committee leaders for suggesting FDA needs to step up its oversight of stem cell products amidst a surge of lawsuits and warning letters sent to violative manufacturers and clinics. “I tend to agree with the House members who sent this letter,” Paul Knoepfler, a professor in the cell biology and human anatomy department at University of California Davis School of Medicine, told Inside Health Policy . “While the FDA has done relatively...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.